Giuseppe V, Masucci

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2023;15(2):418
Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer
Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grutzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Van Lent-van Vliet S; Knijn N; Musing A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pages F; Galon J
Article: CANCERS. 2022;14(18):4346
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study
Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; Van Lent-van Vliet S; Knijn N; Muaina A-M; Scripcariu D-V; Marincola FM; Ascierto PA; Fox BA; Pages F; Kawakami Y; Galon J
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2022;36:91-98
Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases
Lindberg S; Onjukka E; Wersall P; Staff C; Lewensohn R; Masucci G; Lindberg K
Article: CANCERS. 2021;13(16):4164
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2021;19(1):132
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
Isgro MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
Article: CANCERS. 2021;13(2):E265-265
Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinoma-A Retrospective Analysis of A Swedish Cohort
Andtback HB; Bjornhagen-Safwenberg V; Shi H; Lui W-O; Masucci GV; Villabona L
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting
Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001472
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges
Cesano A; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Rutella S
Article: CANCERS. 2020;12(11):E3238-3238
Prognostic Interactions between FAP plus Fibroblasts and CD8a+T Cells in Colon Cancer
Herrera M; Mezheyeuski A; Villabona L; Corvigno S; Strell C; Klein C; Holzlwimmer G; Glimelius B; Masucci G; Sjoblom T; Ostman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(31):3638-3651
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Musina A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pages F; Galon J
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001389
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges
Rutella S; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Cesano A
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):e22063
Effectiveness of PD1-inhibitors in advanced Merkel cell carcinoma: Real life data in a Swedish cohort.
Bjorn-Andtback H; Masucci GV; Villabona LEE
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2019;17(1):234
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Ascierto PA; Agarwala SS; Botti G; Budillon A; Davies MA; Dummer R; Ernstoff M; Ferrone S; Formenti S; Gajewski TF; Garbe C; Hamid O; Lo RS; Luke JJ; Michielin O; Palmieri G; Zitvogel L; Marincola FM; Masucci G; Caraco C; Thurin M; Puzanov I
Article: MOLECULAR ONCOLOGY. 2019;13(2):376-391
Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer
Franzen B; Alexeyenko A; Kamali-Moghaddam M; Hatschek T; Kanter L; Ramqvist T; Kierkegaard J; Masucci G; Auer G; Landegren U; Lewensohn R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2018;16(1):207
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Ascierto PA; Puzanov I; Agarwala SS; Bifulco C; Botti G; Caraco C; Ciliberto G; Davies MA; Dummer R; Ferrone S; Gajewski TF; Garbe C; Luke JJ; Marincola FM; Masucci G; Mehnert JM; Mozzillo N; Palmieri G; Postow MA; Schoenberger SP; Wang E; Thurin M
Article: LANCET. 2018;391(10135):2128-2139
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Pages F; Mlecnik B; Marliot F; Bindea G; Ou F-S; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Ina A-MM; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Article: EUROPEAN JOURNAL OF CANCER. 2017;86:115-124
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Petrella TM; Robert C; Richtig E; Miller WHJ; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2017;15(1):212
World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016
Galon J; Lugli A; Bifulco C; Pages F; Masucci G; Marincola FM; Ascierto PA
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(10):1333-1344
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lovgren T; Sarhan D; Truxova I; Choudhary B; Maas R; Melief J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4(Suppl 2):91
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
Althammer S; Steele K; Rebelatto M; Tan TH; Wiestler T; Schmidt G; Higgs B; Li X; Shi L; Jin X; Antal J; Gupta A; Ranade K; Binning G; Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Puhlmann M; Perini RF; Bajorin DF; Sharma P; Callahan MK; Calvo E; Kim JW; de Braud F; Ott PA; Bono P; Pillai RN; Morse M; Le DT; Taylor M; Spilliopoulou P; Bendell J; Jaeger D; Chan E; Antonia SJ; Ascierto PA; Hennicken D; Tschaika M; Azrilevich A; Rosenberg J; Levy O; Chan C; Cojocaru G; Liang S; Ophir E; Ganguly S; Toporik A; Kotturi M; Kfir TF; Murter BM; Logronio K; Dassa L; Leung L; Greenwald S; Azulay M; Kumar S; Alteber Z; Pan X; Machlenkin A; Benita Y; Drake AW; Chajut A; Salomon R; Vankin I; Safyon E; Hunter J; Levine Z; White M; Leidner R; Kang H; Haddad R; Segal NH; Wirth LJ; Ferris RL; Hodi FS; Sanborn RE; Gajewski TF; Sharfman W; McDonald D; Srivastava S; Gu X; Phillips P; Passey C; Seiwert T; Habtetsion T; Zhou G; Sakellariou-Thompson D; Haymaker C; Creasy C; Hurd M; Uraoka N; Canales JR; Koptez S; Hwu P; Maitra A; Bernatchez C; Coyle SM; Roybel KT; Rupp LJ; Santoro SP; Secrest S; Spelman M; Ho H; Gomes T; Tse T; Yung-Wu C; Taunton J; Lim W; Emtage P; Moudgil T; Ballesteros-Merino C; Hilton T; Paustian C; Leidner R; Page D; Urba W; Fox B; Bell B; Patel A; Olafsen T; Satpayev D; Torgov M; Marchioni F; Romero J; Jiang ZK; Zamilpa C; Keppler JS; Mascioni A; Jia F; Lee C-Y; Gudas J; Sullivan RJ; Hoshida Y; Logan T; Khushalani N; Giobbie-Hurder A; Margolin K; Roder J; Bhatt R; Koon H; Olencki T; Hutson T; Curti B; Blackmon S; Mier JW; Puzanov I; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Signoretti S; McDermott DF; Anderson AA; Puzanov I; Milhem MM; Andtbacka RHI; Minor D; Gorski KS; Baker DM; Hamid O; Kaufman HL; Akporiaye E; Curti B; Koguchi Y; Leidner R; Sutcliffe K; Conder K; Urba W; Marron T; Bhardwaj N; Hammerich L; George F; Kim-Schulze S; Keler T; Davis T; Crowley E; Salazar A; Brody J; Monjazeb A; Daly ME; Riess J; Li T; Murphy WJ; Kelly K; Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswam B; London CA; Xu T; Carson W; Kokolus KM; Repasky EA; Schell TD; Drabick JD; Messenheimer DJ; Jensen S; Fox B; Rubinstein M; Andrijauskaite K; Swiderska-syn M; Lind K; Choppin A; Roell MK; Wrangle J; Andrijauskaite K; Swiderska-syn M; Rhode P; Wong H; Rubinstein M; Ahmad S; Webb M; Abu-Eid R; Shrimali R; Verma V; Doroodchi A; Berrong Z; Yashar D; Samara R; Mkrtichyan M; Khleif S; Powell S; Gitau M; Sumey C; Terrell A; Lohr M; Nowak RK; McGraw S; Jensen A; Blanchard M; Gold KA; Cohen EEW; Ellison C; Black L; Lee J; Spanos WC; Wennerberg E; Schwitzer E; Lhuillier C; Koelwyn G; Hiner R; Jones L; Demaria S; Amanda V; Greiner JW; Schlom J; Bookstaver M; Jewell CM; Paustian C; Gunderson A; Boulmay B; Li R; Spieler B; Happel K; Moudgil T; Feng Z; Ballesteros-Merino C; Dubay C; Fisher B; Koguchi Y; Aung S; Mederos E; Bifulco CB; McNamara M; Bahjat K; Redmond W; Ochoa A; Hu H-M; Mehta A; Lund-Johansen F; Fox B; Urba W; Sanborn RE; Hilton T; Bedu-Addo F; Conn G; King M; Dutta P; Shepard R; Einstein M; Adams S; Wang E; Jin P; Novik Y; Morrison D; Oratz R; Marincola FM; Stroncek D; Goldberg J; Demaria S; Formenti SC; Galon J; Mlecnik B; Marliot F; Ou F-S; Bifulco CB; Lugli A; Zlobec I; Rau TT; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Roehrl MH; Bavi P; Ohashi PS; Wang JY; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Kawakami Y; Papivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Itoh K; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Torigoe T; Sato N; Furuhata T; Takemasa I; Van den Eynde M; Jouret-Mourin A; Machiels J-P; Fredriksen T; Lafontaine L; Buttard B; Church S; Maby P; Angell H; Angelova M; Vasaturo A; Bindea G; Berger A; Lagorce C; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Masucci GV; Andersson EK; Grizzi F; Laghi L; Botti G; Tatangelo F; Delrio P; Cilberto G; Ascierto PA; Marincola F; Sargent DJ; Fox BA; Algazi A; Tsai K; Rosenblum M; Nandoskar P; Andtbacka RHI; Li A; Nonomura J; Takamura K; Dwyer M; Browning E; Talia R; Twitty C; Gargosky S; Campbell J; Ballesteros-Merino C; Bifulco CB; Fox B; Le M; Pierce RH; Daud A; Gartrell R; Marks D; Stack E; Lu Y; Izaki D; Beck K; Jia DT; Armenta P; White-Stern A; Fu Y; Blake Z; Kaufman HL; Taback B; Horst B; Saenger YM; Leonardo S; Gorden K; Fulton RB; Fraser K; Kangas TO; Walsh R; Ertelt K; Graff J; Uhlik M; Sims JS; Lei L; Tsujiuchi T; Bruce JN; Canoll P; Tolcher AW; Alley EW; Chichili G; Canoll JE; Moore P; Bonvini E; Johnson S; Shankar S; Vasselli J; Wigginton J; Powderly J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):313
Future perspectives in melanoma research
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14:273
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon J; Fox BA; Bifulco CB; Masucci G; Rau T; Botti G; Marincola FM; Ciliberto G; Pages F; Ascierto PA; Capone M
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):65
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Nanda VGY; Peng W; Hwu P; Davies MA; Ciliberto G; Fattore L; Malpicci D; Aurisicchio L; Ascierto PA; Croce CM; Mancini R; Spranger S; Gajewski TF; Wang Y; Ferrone S; Vanpouille-Box C; Wennerberg E; Pilones KA; Formenti SC; Demaria S; Tang H; Wang Y; Fu Y-X; Dummer R; Puzanov I; Tarhini A; Chauvin J-M; Pagliano O; Fourcade J; Sun Z; Wang H; Sanders C; Kirkwood JM; Chen T-HT; Maurer M; Korman AJ; Zarour HM; Stroncek DF; Huber V; Rivoltini L; Thurin M; Rau T; Lugli A; Pagès F; Camarero J; Sancho A; Jommi C; de Coaña YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R; Scognamiglio G; Sabbatino F; Marino FZ; Anniciello AM; Cantile M; Cerrone M; Scala S; D’alterio C; Ianaro A; Cirin G; Liguori G; Bott G; Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Testori A; Lorigan P; Sosman JA; Flaherty KT; Yue H; Coleman S; Caro I; Hauschild A; McArthur GA; Sznol M; Callahan MK; Kluger H; Postow MA; Gordan R; Segal NH; Rizvi NA; Lesokhin A; Atkins MB; Burke MM; Ralabate A; Rivera A; Kronenberg SA; Agunwamba B; Ruisi M; Horak C; Jiang J; Wolchok J; Ascierto PA; Liszkay G; Maio M; Mandalà M; Demidov L; Stoyakovskiy D; Thomas L; de la Cruz-Merino L; Atkinson V; Dutriaux C; Garbe C; Wongchenko M; Chang I; Koralek DO; Rooney I; Yan Y; Dréno B; Sullivan R; Patel M; Hodi S; Amaria R; Boasberg P; Wallin J; He X; Cha E; Richie N; Ballinger M; Smith DC; Bauer TM; Wasser JS; Luke JJ; Balmanoukian AS; Kaufman DR; Zhao Y; Maleski J; Leopold L; Gangadhar TC; Long GV; Michielin O; VanderWalde A; Andtbacka RHI; Cebon J; Fernandez E; Malvehy J; Olszanski AJ; Gause C; Chen L; Chou J; Stephen Hodi F; Brady B; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Lebbé C; Ny L; Chacon M; Queirolo P; Loquai C; Cheema P; Berrocal A; Eizmendi KM; Bar-Sela G; Horak C; Hardy H; Weber JS; Grob J-J; Marquez-Rodas I; Schmidt H; Briscoe K; Baurain J-F; Wolchok JD; Pinto R; De Summa S; Garrisi VM; Strippoli S; Azzariti A; Guida G; Guida M; Tommasi S; Jacquelot N; Enot D; Flament C; Pitt JM; Vimond N; Blattner C; Yamazaki T; Roberti M-P; Vetizou M; Daillere R; Poirier-Colame V; la Semeraro M; Caignard A; Slingluff CL; Sallusto F; Rusakiewicz S; Weide B; Marabelle A; Kohrt H; Dalle S; Cavalcanti A; Kroemer G; Di Giacomo AM; Maio M; Wong P; Yuan J; Umansky V; Eggermont A; Zitvogel L; Anna P; Marco T; Stefania S; Francesco M; Mariaelena C; Gabriele M; Antonio AP; Franco S; Roberti MP; Enot DP; Semeraro M; Jégou S; Flores C; Chen T-HT; Kwon BS; Anderson AC; Borg C; Aubin F; Ayyoub M; De Presbiteris AL; Cordaro FG; Camerlingo R; Fratangelo F; Mozzillo N; Pirozzi G; Patriarca EJ; Caputo E; Motti ML; Falcon R; Miceli R; Capone M; Madonna G; Mallardo D; Carrier MV; Panza E; De Cicco P; Armogida C; Ercolano G; Botti G; Cirino G; Sandru A; Blank M; Balatoni T; Olasz J; Farkas E; Szollar A; Savolt A; Godeny M; Csuka O; Horvath S; Eles K; Shoenfeld Y; Kasler M; Costantini S; Capone F; Moradi F; Berglund P; Leandersson K; Linnskog R; Andersson T; Prasad CP; Nigro CL; Lattanzio L; Wang H; Proby C; Syed N; Occelli M; Cauchi C; Merlano M; Harwood C; Thompson A; Crook T; Bifulco K; Ingangi V; Minopoli M; Ragone C; Pessi A; Mannavola F; D’Oronzo S; Felici C; Tucci M; Doronzo A; Silvestris F; Ferretta A; Guida S; Maida I; Cocco T; Passarelli A; Quaresmini D; Franzese O; Palermo B; Di Donna C; Sperduti I; Foddai M; Stabile H; Gismondi A; Santoni A; Nisticò P; Sponghini AP; Platini F; Marra E; Rondonotti D; Alabiso O; Fierro MT; Savoia P; Stratica F; Quaglino P; Di Monta G; Corrado C; Di Marzo M; Ugo M; Di Cecilia ML; Nicola M; Fusciello C; Marra A; Guarrasi R; Baldi C; Russo R; Di Giulio G; Faiola V; Zeppa P; Pepe S; Gambale E; Carella C; Di Paolo A; De Tursi M; Marra L; De Murtas F; Sorrentino V; Voinea S; Panaitescu E; Bolovan M; Stanciu A; Cinca S; Botti C; Aquino G; Anniciello A; Fortes C; Mastroeni S; Caggiati A; Passarelli F; Zappalà A; Capuano M; Bono R; Nudo M; Marino C; Michelozzi P; De Biasio V; Battarra VC; Formenti S; Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL; Gnjatic S; Nataraj S; Imai N; Rahman A; Jungbluth AA; Pan L; Venhaus R; Park A; Lehmann FF; Lendvai N; Cohen AD; Cho HJ; Daniel S; Hirsh V
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13(Suppl 1):o7
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
Pico de Coaña Y; Wolodarski M; Gentilcore G; Yoshimoto Y; Poschke I; Hansson J; Masucci GV; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13:374
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Mc Arthur G; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: TRANSLATIONAL RESEARCH. 2015;166(2):207-217
Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome
Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 3):p231
Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
Pico de Coaña Y; Poschke I; Yoshimoto Y; Karlberg S; Nyström M; Wolodarski M; Hansson J; Masucci G; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12:277
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Ascierto PA; Grimaldi AM; Anderson AC; Bifulco C; Cochran A; Garbe C; Eggermont AM; Faries M; Ferrone S; Gershenwald JE; Gajewski TF; Halaban R; Hodi FS; Kefford R; Kirkwood JM; Larkin J; Leachman S; Maio M; Marais R; Masucci G; Melero I; Palmieri G; Puzanov I; Ribas A; Saenger Y; Schilling B; Seliger B; Stroncek D; Sullivan R; Testori A; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(10):1061-1071
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Poschke I; Lovgren T; Adamson L; Nystrom M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MODERN PATHOLOGY. 2014;27(9):1296-1305
A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA
Villabona L; Leon Rodriguez DA; Andersson EK; Seliger B; Dalianis T; Masucci GV
Article: ANTICANCER RESEARCH. 2014;34(5):2369-2375
HLA-A*02 in Relation to Outcome in Human Papillomavirus Positive Tonsillar and Base of Tongue Cancer
Tertipis N; Villabona L; Nordfors C; Nasman A; Ramqvist T; Vlastos A; Masucci G; Dalianis T
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12(Suppl 1):o9
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production
Gentilcore G; Pico de Yago C; Poschke I; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: METHODS IN MOLECULAR BIOLOGY. 2014;1102:353-366
Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis.
Villabona L; Andersson E; Marchesi M; Masucci GV
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: PLOS ONE. 2013;8(10):e77025
HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome
Nasman A; Andersson E; Marklund L; Tertipis N; Hammarstedt-Nordenvall L; Attner P; Nyberg T; Masucci GV; Munck-Wikland E; Ramqvist T; Dalianis T
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;132(1):72-81
MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome
Nasman A; Andersson E; Nordfors C; Grun N; Johansson H; Munck-Wikland E; Massucci G; Dalianis T; Ramqvist T
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(8):1243-1253
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):827-838
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:214
Defining the critical hurdles in cancer immunotherapy
Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Hakansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinsk P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner J-P; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJP; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
Article: LAKARTIDNINGEN. 2011;108(20):1092-1093
[Paradigmatic shift in oncology: individualized melanoma treatment].
Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Article: CLINICAL CANCER RESEARCH. 2011;17(10):3064-3076
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield LH; Palucka AK; Britten CM; Dhodapkar MV; Hakansson L; Janetzki S; Kawakami Y; Kleen T-O; Lee PP; Maccalli C; Maecker HT; Maino VC; Maio M; Malyguine A; Masucci G; Pawelec G; Potter DM; Rivoltini L; Salazar LG; Schendel DJ; Slingluff CLJ; Song W; Stroncek DF; Tahara H; Thurin M; Trinchieri G; van Der Burg SH; Whiteside TL; Wigginton JM; Marincola F; Khleif S; Fox BA; Disis ML
Article: PHARMACEUTICAL STATISTICS. 2011;10(3):218-226
Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas
Zohar S; Baldi I; Forni G; Merletti F; Masucci G; Gregori D
Article: CANCER RESEARCH. 2010;70(11):4335-4345
Immature Immunosuppressive CD14⁺HLA-DR^-/low Cells in Melanoma Patients Are Stat3^hi and Overexpress CD80, CD83, and DC-Sign
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER RESEARCH. 2010;70(7):2604-2612
A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini P-L; Masucci G; Forni G; Cavallo F
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(10):1599-1608
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Journal article: CELL BIOLOGY INTERNATIONAL. 2009;33(8):816-829
Tissue-specific expression of dentin sialophosphoprotein (DSPP) and its polymorphisms in mouse tissues
Yuan G; Wang Y; Gluhak-Heinrich J; Yang G; Chen L; Li T; Wu L-A; Chen Z; MacDougall M; Chen S
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: HLA. 2007;70(3):205-213
Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer
Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(18_suppl):21059
Lack of p21/Waf-1 expression and lymphocyte infiltration in primary ovarian cancer correlate with the somatic HLA-A2 expression
Andersson E; Villabona L; Kanter L; Gamzatova Z; Kiessling R; Dalianis T; Bergfeldt K; Masucci GV
Article: GYNECOLOGIC ONCOLOGY. 2006;103(1):145-150
Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Article: MELANOMA RESEARCH. 2006;16(4):357-363
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
Masucci GV; Mansson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(18_suppl):14543
High frequency of human leucocyte antigen (HLA) A2 and HLA-B7, -B44, -B15 and -DRB1–4 haplotypes in Swedish prostate cancer patients
Masucci GV; Andersson E; Egevad L; Kälkner K; Harmenberg U; Ryberg M; Nilsson S; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(18_suppl):20100
Swedish ovarian cancer patients are found with a high frequency of human leucocyte antigen (HLA) A2, -B7, -B12, -B15 -B44 and -DRB1–4 haplotypes
Bergfeldt K; Gamzatova Z; Tholander B; Bergdahl M; Nordström B; Hjerpe E; Masucci G
Article: CANCER RESEARCH. 2006;66(12):6387-6394
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: IMMUNOLOGY LETTERS. 2005;100(2):113-119
Effects of human plasma proteins on maturation of monocyte-derived dendritic cells
Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartunková J; Masucci G; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):5054
High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patients
Bergfeldt K; Hising C; Gamzatova Z; Tholander B; Åvall-Lundqvist E; van der Zanden HGM; Masucci G
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):5096
Human leucocyte antigen (HLA) A2 phenotype incidence in patients with advanced ovarian cancer as negative clinical prognostic factor
Masucci GV; Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Åvall-Lundqvist E; Bergfeldt K
Article: MEDICAL ONCOLOGY. 2005;22(3):247-256
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy - A multicenter open randomized phase III study
Masucci G; Broman P; Kelly C; Lindahl S; Malmberg L; Reizenstein J; Ålenius M; Lewensohn R
Journal article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2004;14:52
178 Association Between Expression of HLA-A2 and Ovarian Cancer
Bergfeldt K; Gamzatova Z; de Petris L; Tholander B; Hising C; Alm C; Bergdahl M; Nordstrom B; van der Zanden HGM; Masucci G
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):7541
Alternating temozolomide and low doses rIL-2 in patients with metastatic melanoma. An open non-randomized phase I/II study
Masucci GV; Djuren-Mårtensson E; Hansson J; Månsson-Brahme E; Ragnarsson-Olding B; Wagenius G
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):7541
Alternating temozolomide and low doses rIL-2 in patients with metastatic melanoma. An open non-randomized phase I/II study
Masucci GV; Djuren-Mårtensson E; Hansson J; Månsson-Brahme E; Ragnarsson-Olding B; Wagenius G
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52
Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer
Malmberg KJ; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin JE; Masucci G; Kiessling R
Article: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2001;23(11):1006-1010
Leakage around voice prosthesis in laryngectomees:: Treatment with local GM-CSF
Margolin G; Masucci G; Kuylenstierna R; Björck G; Hertegård S; Karling J
Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s19
Specific vaccination based on the Her2/neu proto-oncogene
Kiessling R; Lindencrona J-A; Charo J; Hising C; Masucci G; Petersson M; Bergh J; Franksson L
Article: JOURNAL OF IMMUNOLOGY. 2001;167(5):2595-2601
Inhibition of activated/memory (CD45RO⁺) T cells by oxidative stress associated with block of NF-κB activation
Malmberg KJ; Arulampalam V; Ichihara F; Petersson M; Seki K; Andersson T; Lenkei R; Masucci G; Pettersson S; Kiessling R
Article: MEDICAL ONCOLOGY. 2001;18(3):231-235
GM-CSF at relatively high topic concentrations can significantly enhance the healing of surgically induced chronic wounds after radiotherapy
Fernberg JO; Brosjö O; Friesland S; Masucci G
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(2):219-230
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marchand M; van Baren N; Weynants P; Brichard V; Dréno B; Tessier MH; Rankin E; Parmiani G; Arienti F; Humblet Y; Bourlond A; Vanwijck R; Liénard D; Beauduin M; Dietrich PY; Russo V; Kerger J; Masucci G; Jäger E; De Greve J; Atzpodien J; Brasseur F; Coulie PG; Van der Bruggen P; Boon T
Article: CANCER RESEARCH. 1997;57(19):4348-4355
Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells
SalazarOnfray F; Nakazawa T; Chhajlani V; Petersson M; Karre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260
Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis)
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: MEDICAL ONCOLOGY. 1996;13(3):149-154
New clinical applications of granulocyte-macrophage colony-stimulating factor
Masucci G
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
Kono K; SalazarOnfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: CANCER RESEARCH, THERAPY AND CONTROL. 1995;4(3):223-229
ANTIBODIES TO EPSTEIN-BARR-VIRUS IN RELATION TO CLINICAL CHARACTERISTICS OF UNTREATED PATIENTS WITH HODGKINS-DISEASE
MERK K; LENNETTE E; HOLM G; JOHANSSON B; MASUCCI G; GRIMFORS G; KLEIN G; BJORKHOLM M
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE. 1994;180(6):2371-2376
INTERLEUKIN-10 PRETREATMENT PROTECTS TARGET-CELLS FROM TUMOR-SPECIFIC AND ALLO-SPECIFIC CYTOTOXIC T-CELLS AND DOWN-REGULATES HLA CLASS-I EXPRESSION
MATSUDA M; SALAZAR F; PETERSSON M; MASUCCI G; HANSSON J; PISA P; ZHANG QJ; MASUCCI MG; KIESSLING R
Journal article: CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY. 1994;71(1):105-112
INTERFERON-GAMMA ENHANCES MONOCLONAL-ANTIBODY 17-1A-DEPENDENT NEUTROPHIL CYTOTOXICITY TOWARD COLORECTAL-CARCINOMA CELL-LINE SW11-16
REALI E; GUILIANI AL; SPISANI S; MORETTI S; GAVIOLI R; MASUCCI G; GAMBARI R; TRANIELLO S
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1993;53(5):751-758
EFFECT OF MONOCLONAL-ANTIBODY 17-1A AND GM-CSF IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA - LONG-LASTING, COMPLETE REMISSIONS CAN BE INDUCED
RAGNHAMMAR P; FAGERBERG J; FRODIN JE; HJELM AL; LINDEMALM C; MAGNUSSON I; MASUCCI G; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1993;10(1-2):61-70
THE THERAPEUTIC USE OF THE UNCONJUGATED MONOCLONAL-ANTIBODIES (MAB) 17-1A IN COMBINATION WITH GM-CSF IN THE TREATMENT OF COLORECTAL-CARCINOMA (CRC)
RAGNHAMMAR P; MAGNUSSON I; MASUCCI G; MELLSTEDT H
Journal article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1993;36(3):191-197
RESTRICTED T-CELL RECEPTOR V-BETA AND J-BETA USAGE IN T-CELLS FROM INTERLEUKIN-2-CULTURED LYMPHOCYTES OF OVARIAN AND RENAL CARCINOMAS
HALAPI E; YAMAMOTO Y; JUHLIN C; JEDDITEHRANI M; GRUNEWALD J; ANDERSSON R; HISING C; MASUCCI G; MELLSTEDT H; KIESSLING R
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1993;10(3):103-111
LOW-DOSE CYCLOPHOSPHAMIDE, ALPHA-INTERFERON AND CONTINUOUS INFUSIONS OF INTERLEUKIN-2 IN ADVANCED RENAL-CELL CARCINOMA
WERSALL JP; MASUCCI G; HJELM AL; RAGNHAMMAR P; FAGERBERG J; FRODIN JE; MERK K; LINDEMALM C; ERICSON K; KALIN B; MELLSTEDT H
Journal article: CANCER JOURNAL. 1993;6(3):116-122
GM-CSF AUGMENTS THE IL-4-INDUCED CYTOTOXIC ACTIVITY OF HUMAN MONONUCLEAR-CELLS IN THE PRESENCE OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A
REALI E; MELLSTEDT H; MASUCCI G
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29A(11):1584-1589
DISEASE-RELATED DIFFERENCES IN ANTIBODY PATTERNS AGAINST EBV-ENCODED NUCLEAR ANTIGENS EBNA-1, EBNA-2 AND EBNA-6
LENNETTE ET; RYMO L; YADAV M; MASUCCI G; MERK K; TIMAR L; KLEIN G
Journal article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1992;35(3):158-164
CYTOTOXIC FUNCTIONS OF BLOOD MONONUCLEAR-CELLS IN PATIENTS WITH COLORECTAL-CARCINOMA TREATED WITH MAB 17-1A AND GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR
RAGNHAMMAR P; MASUCCI G; FRODIN JE; HJELM AL; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1992;9(1):25-33
DIVERSE EFFECT OF CYTOKINE TREATMENT OF TUMOR-CELLS ON SPECIFIC VERSUS NONSPECIFIC CYTOTOXICITY
NAGANUMA H; HALAPI E; MASUCCI G; HANSSON M; WERSALL P; HISING C; VENKATESWARAN S; MELLSTEDT H; KIESSLING R
Journal article: SEMINARS IN ONCOLOGY. 1991;18(5):462-477
THE THERAPEUTIC USE OF MONOCLONAL-ANTIBODIES IN COLORECTAL-CARCINOMA
MELLSTEDT H; FRODIN JE; MASUCCI G; RAGNHAMMAR P; FAGERBERG J; HJELM AL; SHETYE J; WERSALL P; OSTERBORG A
Journal article: HYBRIDOMA. 1991;10(4):421-431
INDUCTION OF ANTIIDIOTYPIC (AB2) AND ANTI-ANTI-IDIOTYPIC (AB3) ANTIBODIES IN PATIENTS TREATED WITH THE MOUSE MONOCLONAL-ANTIBODY 17-1A (AB1) - RELATION TO THE CLINICAL OUTCOME - AN IMPORTANT ANTITUMORAL EFFECTOR FUNCTION
FRODIN JE; FAXAS ME; HAGSTROM B; LEFVERT AK; MASUCCI G; NILSSON B; STEINITZ M; UNGER P; MELLSTEDT H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1991;48(3):344-349
PATIENTS TREATED WITH A MONOCLONAL-ANTIBODY (AB1) TO THE COLORECTAL-CARCINOMA ANTIGEN-17-1A DEVELOP A CELLULAR-RESPONSE (DTH) TO THE INTERNAL IMAGE OF THE ANTIGEN (AB2)
MELLSTEDT H; FRODIN JE; BIBERFELD P; FAGERBERG J; GISCOMBE R; HERNANDEZ A; MASUCCI G; LI SL; STEINITZ M
Journal article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1991;33(1):45-49
INTERLEUKIN-4 AUGMENTS THE CYTOTOXIC CAPACITY OF LYMPHOCYTES AND MONOCYTES IN ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
WERSALL P; MASUCCI G; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1991;8(3):207-220
CHEMOTHERAPY AND IMMUNOTHERAPY OF COLORECTAL-CANCER
MASUCCI G; RAGNHAMMAR P; FRODIN JE; HJELM AL; WERSALL P; FAGERBERG J; OSTERBORG A; MELLSTEDT H
Journal article: ACTA ONCOLOGICA. 1991;30(8):923-931
THERAPY OF COLORECTAL-CARCINOMA WITH MONOCLONAL-ANTIBODIES (MAB17-1A) ALONE AND IN COMBINATION WITH GRANULOCYTE MONOCYTE-COLONY STIMULATING FACTOR (GM-CSF)
MELLSTEDT H; FRODIN JE; RAGNHAMMAR P; MASUCCI G; LJUNGBERG A; HJELM AL; FAGERBERG J; LINDEMALM C; OSTERBORG A; WERSALL P; CHRISTENSSON B; SHETYE J; BIBERFELD P; MAKOWER J; CEDERMARK B; ERWALD R; NATHANSSON J; MAGNUSSON I; RIEGER A
Journal article: CANCER JOURNAL. 1991;4(3):168-173
COMBINATIONS OF IL-2, GM-CSF, IL-4, IFN-ALPHA AND TNF-ALPHA INCREASE THE ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) OF BLOOD MONONUCLEAR-CELLS IN PRESENCE OF EITHER MOUSE OR CHIMERIC MAB 17-1A - A PRECLINICAL EVALUATION
MASUCCI G; MELLSTEDT H
Journal article: LEUKEMIA RESEARCH. 1991;15(10):963
New aspects in the diagnosis and treatment of Hodgkin's disease In recent results in cancer research, edited by Diehl V., Pfreundschuh M. & Löffler M. (Springer, Berlin, 1990)
Masucci G
Journal article: LEUKEMIA. 1990;4(2):81-82
BIOLOGIC THERAPEUTICS AS THE 4TH MODALITY IN CANCER-TREATMENT
MASUCCI G; MELLSTEDT H
Journal article: ACTA ONCOLOGICA. 1990;29(4):431-437
GENERATION OF HUMAN LAK CELLS IN TISSUE-CULTURE BAGS USING RECOMBINANT IL-2 AND SERUM FREE MEDIUM - EFFECTS OF PRETREATMENT WITH PHENYLALANINE-METHYLESTER
WERSALL P; MASUCCI G; PIHLSTEDT P; COTGREAVE I; TRIBUKAIT B; ULLBERG M; WIGZELL H; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1990;7(4):257-263
SIMPLIFIED LONG-TERM LARGE-SCALE PRODUCTION OF HIGHLY-ACTIVE HUMAN LAK CELLS FOR THERAPY
WERSALL P; MASUCCI G; PIHLSTEDT P; WIGZELL H; MELLSTEDT H
Journal article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1990;31(4):231-235
GRANULOCYTE-MONOCYTE COLONY-STIMULATING-FACTOR AUGMENTS THE INTERLEUKIN-2-INDUCED CYTOTOXIC ACTIVITY OF HUMAN-LYMPHOCYTES IN THE ABSENCE AND PRESENCE OF MOUSE OR CHIMERIC MONOCLONAL-ANTIBODIES (MAB 17-1A)
MASUCCI G; RAGNHAMMAR P; WERSALL P; MELLSTEDT H
Journal article: ONCOLOGY-NEW YORK. 1989;3(12):25-32
Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma.
Mellstedt H; Frodin JE; Masucci G
Journal article: HYBRIDOMA. 1989;8(5):507-516
LYMPHOKINE ACTIVATED KILLER (LAK) CELLS IN ANTIBODY DEPENDENT CELLULAR CYTO-TOXICITY (ADCC) USING MAB 17-1A - A COMBINATION OF POTENTIAL USEFULNESS IN TUMOR-THERAPY
MASUCCI G; WERSALL P; NIELSEN J; NIELSEN HK; WIGZELL H; MELLSTEDT H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1989;43(6):1017-1021
RELATIONSHIP BETWEEN CLINICAL STAGE, HISTOPATHOLOGY AND ANTIBODY-TITERS AGAINST THE 2ND EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN (EBNA-2) IN NON-HODGKINS LYMPHOMA PATIENTS
MASUCCI G; MELLSTEDT H; HENLE G; HENLE W; RYMO L; MASUCCI MG; ERNBERG I; KLEIN G
Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1989;24(3):257-268
BIOLOGIC RESPONSE MODIFIERS IN THE TREATMENT OF GASTROINTESTINAL MALIGNANCIES
MELLSTEDT H; FRODIN JE; LINDEMALM C; MASUCCI G; MERK K; PETTERSSON D; RAGNHAMMAR P; STEINITZ M; WEDELIN C; WERSALL P; OSTERBORG A
Journal article: ACTA CHIRURGICA SCANDINAVICA, SUPPLEMENT. 1989;549:63-70
MONOCLONAL-ANTIBODIES (MAB 17-1A) FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMAS
MELLSTEDT H; FRODIN JE; MASUCCI G; LINDEMALM C; WEDELIN C; CHRISTENSSON B; SHETYE J; BIBERFELD P; LEFVERT AK; PIHLSTEDT P; MAKOWER J
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1989;6(1):99-107
THE CLINICAL USE OF MONOCLONAL-ANTIBODIES, MAB 17-1A, IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA
MELLSTEDT H; FRODIN JE; RAGNHAMMAR P; MASUCCI G; SHETYE J; CHRISTENSSON B; BIBERFELD P; MAKOWER J; PIHLSTEDT P; CEDERMARK B; HARMENBERG U; WAHREN B; RIEGER A; MAGNUSSON I; NATHANSSON J; ERWALD R
Journal article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1989;29(4):288-292
GRANULOCYTE-MONOCYTE-COLONY-STIMULATING FACTOR AUGMENTS THE CYTO-TOXIC CAPACITY OF LYMPHOCYTES AND MONOCYTES IN ANTIBODY-DEPENDENT CELLULAR CYTO-TOXICITY
MASUCCI G; WERSALL P; RAGNHAMMAR P; MELLSTEDT H
Journal article: HYBRIDOMA. 1988;7(5):429-440
EFFECT OF HUMAN-BLOOD MONONUCLEAR CELL-POPULATIONS IN ANTIBODY DEPENDENT CELLULAR CYTO-TOXICITY (ADCC) USING 2 MURINE (CO17-1A AND BR55-2) AND ONE CHIMERIC (17-1A) MONOCLONAL-ANTIBODIES AGAINST A HUMAN COLORECTAL-CARCINOMA CELL-LINE (SW948)
MASUCCI G; LINDEMALM C; FRODIN JE; HAGSTROM B; MELLSTEDT H
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1987;23(4):379-386
ANALYSIS OF EPSTEIN-BARR VIRUS-SPECIFIC AND NONSPECIFIC IMMUNE FUNCTIONS IN A PATIENT DURING THE DEVELOPMENT OF A NON-HODGKINS-LYMPHOMA
MASUCCI G; MELLSTEDT H; MASUCCI MG; ERNBERG I; SZIGETI R; HENLE G; HENLE W; KLEIN G
Journal article: IMMUNOLOGY LETTERS. 1985;9(5):267-273
LEUKOCYTE MIGRATION-INHIBITORY FACTOR PRODUCTION BY ACTIVATED LYMPHOCYTES REPRESENTING IMMUNOLOGICAL MEMORY OR VIRUS-RECEPTOR INTERACTION - RESPONSE OF T-CELL SUBSETS TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN, RESPONSE OF B-CELLS TO UV INACTIVATED EPSTEIN-BARR VIRUS
SZIGETI R; MASUCCI MG; MASUCCI G; AMAN P; KLEIN G; KLEIN E
Journal article: JOURNAL OF CLINICAL IMMUNOLOGY. 1984;4(5):369-382
EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CELL-MEDIATED AND HUMORAL IMMUNE-RESPONSES IN ATAXIA-TELANGIECTASIA PATIENTS
MASUCCI G; BERKEL I; MASUCCI MG; ERNBERG I; SZIGETI R; ERSOY F; SANAL O; YEGIN O; HENLE G; HENLE W; PEARSON G; AMAN P; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1984;85(2):511-518
PRODUCTION OF LEUKOCYTE MIGRATION-INHIBITORY FACTOR (LIF) IN HUMAN-LYMPHOCYTE SUBSETS EXPOSED TO POLYCLONAL ACTIVATORS
MASUCCI G; SZIGETI R; STEVENS D; MASUCCI MG; KLEIN E; PETERSEN J; BENDTZEN K; KLEIN G
Journal article: CANCER RESEARCH. 1984;44(3):1288-1300
IMMUNOLOGICAL CHARACTERIZATION OF HODGKINS AND NON-HODGKINS LYMPHOMA PATIENTS WITH HIGH ANTIBODY-TITERS AGAINST EPSTEIN-BARR VIRUS-ASSOCIATED ANTIGENS
MASUCCI G; MELLSTEDT H; MASUCCI MG; SZIGETI R; ERNBERG I; BJORKHOLM M; TSUKUDA K; HENLE G; HENLE W; PEARSON G; HOLM G; BIBERFELD P; JOHANSSON B; KLEIN G
Journal article: CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY. 1984;30(3):437-450
VIROLOGIC, IMMUNOLOGICAL, AND CLINICAL OBSERVATIONS ON A PATIENT DURING THE INCUBATION, ACUTE, AND CONVALESCENT PHASES OF INFECTIOUS MONONUCLEOSIS
SVEDMYR E; ERNBERG I; SEELEY J; WEILAND O; MASUCCI G; TSUKUDA K; SZIGETI R; MASUCCI MG; BLOMGREN H; BERTHOLD W; HENLE W; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1984;83(1):136-141
EBNA-SPECIFIC LIF PRODUCTION OF HUMAN-LYMPHOCYTE SUBSETS
SZIGETI R; MASUCCI G; EHLINHENRIKSSON B; BENDTZEN K; HENLE G; HENLE W; KLEIN G; KLEIN E
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1983;32(5):609-616
GAMMA-INTERFERON (IFN-GAMMA) PRODUCED DURING EFFECTOR AND TARGET INTERACTIONS RENDERS TARGET-CELLS LESS SUSCEPTIBLE TO NK-CELL-MEDIATED LYSIS
GRONBERG A; KIESSLING R; MASUCCI G; GUEVARA LA; ERIKSSON E; KLEIN G
Journal article: JOURNAL OF IMMUNOLOGICAL METHODS. 1983;63(1):57-67
COMPARISON OF HIGHLY NK ACTIVE HUMAN-LYMPHOCYTE SUBSETS SEPARATED BY VARIOUS PROCEDURES INVOLVING E, EA ROSETTING, DENSITY GRADIENTS AND ADHERENCE TO IMMUNE-COMPLEXES
MASUCCI G; MASUCCI MG; BEJARANO MT; KLEIN E
Journal article: CELLULAR IMMUNOLOGY. 1983;76(2):311-321
LARGE GRANULAR LYMPHOCYTES INHIBIT THE INVITRO GROWTH OF AUTOLOGOUS EPSTEIN-BARR VIRUS-INFECTED B-CELLS
MASUCCI MG; BEJARANO MT; MASUCCI G; KLEIN E
Journal article: MOLECULAR IMMUNOLOGY. 1982;19(10):1323-1329
NATURAL-KILLER ACTIVITY OF HUMAN-BLOOD LYMPHOCYTES
KLEIN E; MASUCCI MG; MASUCCI G; VANKY F
Journal article: ORVOSI HETILAP. 1982;123(20):1217-1221
[Leukocyte migration inhibition elicited by Epstein-Barr virus antigen. Reaction potential in infectious mononucleosis as well as in states of immune deficiency and immunosuppression].
Szigeti R; Klein E; Masucci MG; Ernberg I; Masucci G; Svedmyr E; Klein G
Journal article: CELLULAR IMMUNOLOGY. 1982;69(1):21-33
ACTIVATION OF HUMAN-BLOOD LYMPHOCYTE SUBSETS FOR CYTO-TOXIC POTENTIAL
MASUCCI G; MASUCCI MG; KLEIN E
Journal article: CELLULAR IMMUNOLOGY. 1982;69(1):166-174
HUMAN-BLOOD LYMPHOCYTE SUBSETS SEPARATED ON THE BASIS OF NYLON ADHERENCE, SRBC AND EA ROSETTING - NATURAL CYTO-TOXICITY AND CHARACTERIZATION WITH MONOCLONAL REAGENTS
MASUCCI G; MASUCCI MG; KLEIN E
Journal article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1982;68(2):179-195
HUMAN LYMPHOMA-LYMPHOMA HYBRIDS AND LYMPHOMA-LEUKEMIA HYBRIDS .1. ISOLATION, CHARACTERIZATION, CELL-SURFACE MARKERS, AND B-CELL MARKERS .7.
ZEUTHEN J; KLEIN G; BER R; MASUCCI G; BISBALLE S; POVEY S; TERASAKI P; RALPH P
Journal article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1982;68(2):179-195
Human Lymphoma-Lymphoma Hybrids and Lymphoma-Leukemia Hybrids. I. Isolation, Characterization, Cell Surface Markers, and B-Cell Markers23
Zeuthen J; Klein G; Ber R; Masucci G; Bisballe S; Povey S; Terasaki P; Ralph P
Journal article: CANCER RESEARCH. 1981;41(11):4292-4301
CELL-MEDIATED IMMUNE-REACTIONS IN 3 PATIENTS WITH MALIGNANT LYMPHOPROLIFERATIVE DISEASES IN REMISSION AND ABNORMALLY HIGH EPSTEIN-BARR VIRUS-ANTIBODY TITERS
MASUCCI MG; SZIGETI R; ERNBERG I; BJORKHOLM M; MELLSTEDT H; HENLE G; HENLE W; PEARSON G; MASUCCI G; SVEDMYR E; JOHANSSON B; KLEIN G
Journal article: CANCER RESEARCH. 1981;41(11):4284-4291
CELLULAR IMMUNE DEFECTS TO EPSTEIN-BARR VIRUS-DETERMINED ANTIGENS IN YOUNG MALES
MASUCCI MG; SZIGETI R; ERNBERG I; MASUCCI G; KLEIN G; CHESSELS J; SIEFF C; LIE S; GLOMSTEIN A; BUSINCO L; HENLE W; HENLE G; PEARSON G; SAKAMOTO K; PURTILO DT
Journal article: CANCER RESEARCH. 1981;41(11):4210-4215
T-CELL RESPONSE TO B-CELLS AND EPSTEIN-BARR VIRUS-ANTIGENS IN INFECTIOUS MONONUCLEOSIS
KLEIN E; ERNBERG I; MASUCCI MG; SZIGETI R; WU YT; MASUCCI G; SVEDMYR E
Journal article: NATURE. 1980;288(5791):594-596
INTERFERON SUPPRESSES ANTIGEN-INDUCED AND MITOGEN-INDUCED LEUKOCYTE MIGRATION-INHIBITION
SZIGETI R; MASUCCI MG; MASUCCI G; KLEIN E; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1980;52(2):247-254
INVITRO GENERATION OF K562 KILLERS IN HUMAN T-LYMPHOCYTE SUBSETS
MASUCCI G; POROS A; SEELEY JK; KLEIN E
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1980;77(6):3620-3624
TARGET SELECTIVITY OF INTERFERON-INDUCED HUMAN KILLER LYMPHOCYTES RELATED TO THEIR FC-RECEPTOR EXPRESSION
MASUCCI MG; MASUCCI G; KLEIN E; BERTHOLD W
Journal article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1980;64(4):725-738
HYBRIDIZATION OF A MYELOID LEUKEMIA-DERIVED HUMAN CELL-LINE (K562) WITH A HUMAN BURKITT-LYMPHOMA LINE (P3HR-1)
KLEIN G; ZEUTHEN J; ERIKSSON I; TERASAKI P; BERNOCO M; ROSEN A; MASUCCI G; POVEY S; BER R
Journal article: SOMATIC CELL GENETICS. 1980;6(1):89-99
SOMATIC HYBRIDS BETWEEN A HIGH NK-SENSITIVE LYMPHOID (YACIR) AND SEVERAL LOW SENSITIVE SARCOMA OR L-CELL-DERIVED MOUSE LINES EXHIBIT LOW SENSITIVITY
AHRLUND-RICHTER L; KLEIN E; MASUCCI G
Journal article: JOURNAL OF IMMUNOLOGY. 1979;123(3):1303-1311
STUDIES ON CYTOTOXICITY GENERATED IN HUMAN MIXED LYMPHOCYTE-CULTURES .2. ANTI-K562 EFFECTORS ARE DISTINCT FROM ALLOSPECIFIC CTL AND CAN BE GENERATED FROM NK-DEPLETED T-CELLS
SEELEY JK; MASUCCI G; POROS A; KLEIN E; GOLUB SH
Journal article: TUMORI JOURNAL. 1977;63(4):381-386
ITALIAN CASE OF NASOPHARYNGEAL CARCINOMA CORRELATED WITH EPSTEIN-BARR VIRUS SPECIFIC ANTIGENS
SCOLOZZI R; MASUCCI G; CASSAI E; PANSINI R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1976;17(2):197-203
PERSISTENCE OF EPSTEIN-BARR VIRAL NUCLEAR ANTIGEN (EBNA) IN CELLS ENTERING EB VIRAL CYCLE
ERNBERG I; MASUCCI G; KLEIN G
Visa fler

Artiklar

Anställningar

Handledning

Nyheter från KI

Kalenderhändelser från KI